BioCentury
ARTICLE | Targets & Mechanisms

AChE revisited

Why Neuro-Bio thinks it's time to revisit the role of AChE in AD

June 30, 2016 7:00 AM UTC

Neuro-Bio Ltd. has identified a peptide derived from AChE - the enzyme responsible for breaking down acetylcholine - and believes the fragment is the main pathological driver in Alzheimer's disease, acting upstream of β-amyloid and tau in the brain centers hit earliest in the disease.

The company, which was formed in 2013, is developing inhibitors of the peptide to create a disease-modifying therapy, and is seeking investors to help fund preclinical studies...